Pay in 4 interest-free payments of $6.05 Learn more
Ships within 48 hours · Estimated delivery Aug 30 - Sep 4
It is a GH secretagogue and an agonist, meaning it may bind to specific cell receptors and cause a physiological reaction
PMID 12596522
MC4R-Mediated Research Pathways MT-2's activity at the melanocortin 4 receptor (MC4R) has opened additional areas of investigation
Moreover, taurine interferes with mitochondria-dependent apoptosis and the unfolded protein response [44], it downregulates the p53-Chk1 pathway [45] and upregulates extracellular-signal-regulated kinases (ERK) and Wnt/-catenin pathway [44, 46]
The most realistic estimate is 2027, assuming Phase 3 trials produce positive results throughout 2026 and Lilly files for FDA approval in late 2026
US$ 25.81
US$ 23.44
US$ 26.18
